AI Integration Advances Cancer Diagnosis and Molecular Testing, Featured at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics to enhance cancer diagnosis and treatment. Researchers at the University of Michigan have developed 'Turnkey Precision Oncology,' an open-source, AI-assisted platform that analyzes DNA and RNA sequencing data to generate evidence-supported molecular pathology reports. Its AI component, TPO-Agent, utilizes established cancer genetics databases and scientific literature to verify interpretations, significantly reducing unsupported conclusions. In an evaluation, approximately 95% of the system's claims were supported by cited evidence, compared to 65% with conventional AI. The broader platform also showed about 95% agreement with clinical laboratory findings across 28 reports. This development, along with other AI advancements in cancer classification and testing optimization, will be a central focus at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, Washington, from November 10–14.